Lexaria Bioscience director McKechnie buys $4.5k in shares

Published 30/07/2025, 17:42
Lexaria Bioscience director McKechnie buys $4.5k in shares

On July 29, 2025, William Edward McKechnie, a director of Lexaria Bioscience Corp (NASDAQ: NASDAQ:LEXX), purchased 5,000 common shares of the company. The shares were bought at a price of $0.9063, totaling $4,531. The purchase comes as LEXX shares have declined over 75% in the past year, though InvestingPro analysis suggests the stock is currently undervalued. The micro-cap company, valued at approximately $18 million, maintains a strong balance sheet with more cash than debt.

Following the transaction, McKechnie directly owns 18,191 common shares of Lexaria Bioscience Corp. He also holds options for 63,000 common shares, at prices ranging from $0.87 to $3.39. While the company maintains a healthy current ratio of 3.9x, InvestingPro subscribers can access 8 additional key insights about LEXX’s financial health and growth prospects.

In other recent news, Lexaria Bioscience has been active with several key developments. The company announced interim results from its Phase 1b GLP-1-H24-4 study in Australia, focusing on its DehydraTECH-semaglutide and DehydraTECH-tirzepatide arms, alongside a Rybelsus control arm. In terms of analyst activity, H.C. Wainwright lowered its price target for Lexaria Bioscience to $4.00 from a previous $5.00, maintaining a Buy rating. This adjustment follows Lexaria’s report of positive partial results from a study comparing its oral DehydraTECH-liraglutide to the injected Saxenda.

Additionally, Lexaria Bioscience has expanded its patent portfolio to 50 with two new international patents, including one in Australia for treating epilepsy. The company has also reported advancements in its collaboration with a pharmaceutical company, PharmaCO, having completed initial pre-clinical studies under a Material Transfer Agreement. PharmaCO is interested in further data from Lexaria’s ongoing independent human study in Australia, which may lead to more collaborative efforts. Lexaria’s DehydraTECH technology has shown the capability to reduce side effects in GLP-1 drugs, addressing significant patient retention challenges in the sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.